Pozelimab + Cemdisiran (C5 Inhibition)
Generalized Myasthenia Gravis
Sponsor Regeneron
235 Enrollment Target
75 Trial Sites
5 Countries
December 2026 Est. Completion
About This Trial
Dual complement inhibition approach combining antibody and siRNA therapy.
Primary Endpoints
- MG-ADL score improvement
- Complete stable remission rate
Latest Update
February 2026
Primary endpoint met with 4.2 point improvement vs placebo. Filing expected H2 2026.